Skip to content

Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance.

Oct 2026 · Diabetologia · 0 citations · 56 references
Medicine

TL;DR

In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin resistance.

View source

Similar papers

Oct 2026

Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals with Type 2 Diabetes from Primary Care and Endocrinology Settings.

OBJECTIVES Current metabolic dysfunction-associated steatotic liver disease (MASLD) guidelines recommend fibrosis screening in individuals with type 2 diabetes (T2D) because of their increased risk of clinically significant fibrosis (≥F2). However, fibrosis risk is variable, and clinical tools to identify individuals a...

N. Cuervo-Pardo, S. Kalavalapalli, Eddison Godinez Leiva et al. · 0 citations
Open access Oct 2026

Hepatic steatosis is associated with postprandial dysglycemia in type 1 diabetes: insights from dual-modality liver assessment

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in type 1 diabetes (T1D), yet its relationship with dynamic glycemic abnormalities and the metabolic pathways underlying these associations remains incompletely understood. We investigated the associations of hepatic...

Shuang Li, Pan-Zun Wang, Zhi-Hong Cai et al. · 0 citations
Oct 2026

A-161 Correlation of Cardiovascular Disease and Diabetes to the Enhanced Liver Fibrosis Score

Roughly 90% of patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have at least one feature of metabolic syndrome, a disease characterized by insulin resistance, obesity, hypertension and hyperlipidemia. MASLD can be accessed by the Enhanced Liver Fibrosis test (ELF, Siemens Healthinee...

C. Orahoske, Shirley Li, Alan H. B. Wu · 0 citations
Oct 2026

Assessment of the effect of fibroscan and anthropometric factors on incidence and progression of non-diabetic metabolic Dysfunction-associated steatotic liver disease.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non- alcoholic fatty liver disease (NAFLD), is a prevalent liver condition characterized by excessive fat accumulation in hepatocytes, primarily due to metabolic risk factors. Steatosis, the initial accumulation of fat, can p...

Pragya Goswami, S. Ray, Abhishek Singhai et al. · 0 citations
Open access Oct 2026

Differential Cardiometabolic Risk Profiles of Lean and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A Longitudinal Health Checkup Cohort Study.

Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes, providing exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.

H. Kawamura, Kei Fujiwara, Ryo Sato et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.